#BCL-2 inhibitors market size | Explore Tumblr posts and blogs

techscimarketresearch · 3 years ago

Text

Senolytic Drugs Market to Grow with Impressive CAGR During the Forecast Period | TechSci Research

Global Senolytic Drugs Market is driven by advancing pharmaceutical industry in the forecast period, 2023-2027.

According to TechSci Research report, “Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027”, the global senolytic drugs market has a potential to project an impressive CAGR toward forces growth in the period, 2023-2027, on the account of increasing demand for anti-aging drugs. Rapidly advancing healthcare sector and expanding pharmaceutical industry is further responsible for the growth of the global senolytic drugs market in the upcoming five years.

Surge in the demand for the advanced pharmaceutical and therapeutics in the major economies is further anticipated to support the growth of the global senolytic drugs market in the next five years. Multiple market players have invested in research and rapidly increasing their financial supports to the research institutes and academic center dedicated toward designing anti-aging drugs and senolytic drugs thus substantiating the growth of the global senolytic drugs market in the future five years.

Increasing instances of chronic diseases like cardiovascular diseases, neurodegenerative diseases, chronic obtrusive pulmonary diseases (COPD), etc. is also raising the demand for the senolytic drugs thus aiding the growth of the global senolytic drugs market in the forecast years, until 2027. Rapidly growing cases of geriatric population suffering from high blood pressure, diabetes, Alzheimer disease and Parkinson disease, are related to the growing age among humans.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Senolytic Drugs Market"

https://www.techsciresearch.com/report/senolytic-drugs-market/8205.html

With increasing geriatric population of the world that may exceed 1 billion counts in next 30 years is also one of the major reasons behind futuristic growth of the global senolytic drugs market in the upcoming five years.

Although, stringent rules and regulations regarding FDA approvals and clinical trials on the developing senolytic drugs may put mild restraint on the growth of the global senolytic drugs market in the future.

The global senolytic drugs market segmentation is based on type, application, distribution channel, regional distribution, and competitive landscape. Based on type, the market is fragmented into FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, and others. Dasatinib, Quercetin, Fisetin and Navitoclax are some of the primarily discovered senolytic drugs through hypothesis.

Pre-clinical functions of the of the senolytic drugs were designed to be preventive toward cancers, and cardiovascular, neuropsychiatric, liver, kidney, musculoskeletal, lung, eye, hematological, metabolic and skin disorders. Also, clinical trials of these drugs against diabetes, idiopathic pulmonary fibrosis, Alzheimer’s disease, COVID-19, osteoarthritis, osteoporosis, eye disease, etc. are continued. The studies are still being conducted and commercialization of these drugs have still not started.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8205 Customers can also request for 10% free customization on this report.

Market segmentation based on application, bifurcates into longevity, senescence inhibition, cardiovascular diseases, neural degenerative diseases, and others. Longevity is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of increasing demand for the pharmaceutical products that can aid healthy lifespan in humans. Rapidly increasing geriatric population of the world is further driving the growth of the global senolytic drugs market in the next five years.

Senescence inhibition is the process of killing the aged cells that are not dividing and accumulating in a location forming tumorous lump. Usually, senescence in cells is a stress response mechanism induced by different type of bodily responses like telomere attrition, DNA damage, and oncogenic mutations, etc. Available therapeutics target such senescent cells act on specific killing of these cells by senolytic process, specific inhibition of the secretory phenotype, and improving removal of senescent cells by immune system.

Some of the market players, dominating the global senolytic drugs market are:

AgeX Therapeutics, Inc.

Cleara Biotech

Eternans Ltd.

FoxBio Inc

Numeric Biotech

T.A. Sciences, Inc.

Recursion Pharmaceuticals, Inc.

The existing market players are highly invested in research and product development along with viable service provisions for the consumers. New market entrants may follow similar strategies along with merger and acquisition methods for future brand establishment.

Press Release: https://www.techsciresearch.com/news/6824-senolytic-drugs-market.html

“North America is anticipated to hold the largest revenue shares of the market and dominate the regional analysis in the upcoming five years on the account of expanding healthcare industry in the region. In the major economies like the United States, and Canada, healthcare sector is booming on the basis of increasing research and advancement in the pharmaceutical sector in the countries along with the increasing investment in the pharmaceutical designing, production and further research over senescent cells. Moreover, government aid along with the FDA approvals for the senolytic drugs is further anticipated to aid the growth of the global senolytic drugs market in the next five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Senolytic Drugs Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027 Segmented By Type (FOXO4-related peptides, bcl-2 Family Inhibitors, Src Tyrosine Kinase Inhibitors, Navitoclax, Dasatinib & Quercetin, Others), By Application (Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region”, has evaluated the future growth potential of global senolytic drugs and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global senolytic drugs market.

Browse Related Reports:

Global Anti-Fungal Drugs Market By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others), By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others), By Infection Type (Superficial Fungal Infection, Systemic Fungal Infection), By Route of Administration (Topical, Oral, Parenteral, Others), By End User (Homecare, Hospitals, Clinics, Others) By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/anti-fungal-drugs-market/7786.html

Global Nuclear Medicine Market By Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine, Brachytherapy Isotopes), By Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals v/s PET Radiopharmaceuticals), By Therapeutic Nuclear Medicine (Alpha Emitters v/s Beta Emitters), By Application (Diagnostic Applications v/s Therapeutic Applications), By Diagnostic Applications (SPECT Applications v/s PET Applications), By Therapeutic Applications (Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutions), By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/nuclear-medicine-market/4562.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Senolytic Drugs Market #Healthcare #Senolytic Drugs Market #Senolytic Drugs Market Size #Senolytic Drugs Market Forecast #Senolytic Drugs #Consumer Healthcare

0 notes

techsciresearch · 3 years ago

Text

Senolytic Drugs Market to Grow with Impressive CAGR During the Forecast Period | TechSci Research

Global Senolytic Drugs Market is driven by advancing pharmaceutical industry in the forecast period, 2023-2027.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Senolytic Drugs Market"

https://www.techsciresearch.com/report/senolytic-drugs-market/8205.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8205 Customers can also request for 10% free customization on this report.

Some of the market players, dominating the global senolytic drugs market are:

AgeX Therapeutics, Inc.

Cleara Biotech

Eternans Ltd.

FoxBio Inc

Numeric Biotech

T.A. Sciences, Inc.

Recursion Pharmaceuticals, Inc.

Press Release: https://www.techsciresearch.com/news/6824-senolytic-drugs-market.html

Browse Related Reports:

https://www.techsciresearch.com/report/anti-fungal-drugs-market/7786.html

https://www.techsciresearch.com/report/nuclear-medicine-market/4562.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Senolytic Drugs Market #Health #Healthcare #Senolytic Drugs Market #Senolytic Drugs Market Size #Senolytic #Senolytic Drugs #Consumer Healthcare #Senolytic Drugs Market Forecast

0 notes

kritikarehani · 3 years ago

Text

Acute Myeloid Leukemia Market Size, Share, Trends, Epidemiology and Market Forecast 2030

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized through clonal proliferation and impaired differentiation of myeloid precursors with various outcomes. Quickest-growing cancer happens when the bone marrow begins to form cells that have not yet absolutely matured as blasts. These cells crowd the bone marrow, stopping it from making normal blood cells and leukemia starts to crowd out the normal white blood cells, crimson blood cells, and platelets that the frame desires. In Acute myeloid leukemia, the bone marrow additionally makes strange crimson cells and platelets. As consequence, the blood cells do not develop, and it gets hard to ward off infections.

Acute Myeloid Leukemia Signs and Symptoms

The symptoms of acute myeloid leukemia generally expand over a week and become an increasing number severely. Signs can include anemia, light skin, constant tiredness, joint infections, frequent bleeding, bone pain, and others.

Acute Myeloid Leukemia Epidemiology

Acute Myeloid Leukemia accounts for <3% of all cancer, and 25% of all leukemia in adults. Worldwide, the incidence of Acute Myeloid Leukemia is reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years. Incidence continuously shows 2 peaks in occurrence in early childhood and later adulthood. From 2000 to 2003, the US incidence rate in people aged <65 years was only 1.8 per 100,000 persons, whereas the incidence rate in people aged 65 years was 17 per 100,000 persons.

The Acute Myeloid Leukemia incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%. A cross-national study using US and England data found that the overall risk of mortality for Acute Myeloid Leukemia was 23% lower in England compared to that in the US. However, survival difference was similar in subgroups of sex and age at diagnosis.

According to a study, the yearly average incidence rate of leukemia was 3.68/105 during 2003-2007 in Nanjing. There were no significant differences in gender, the incidence rate was the highest in the group aged 80~ years.

Acute Myeloid Leukemia Treatment Options

Acute Myeloid Leukemia is common leukemia affecting adults and poses a major medical challenge with increased mortality and morbidity. Once diagnosed, the treatment needs to start as quickly as possible. The treatment depends on age, risk factors, and the sub-types of Acute Myeloid Leukemia.

The aim of treatment for Acute Myeloid Leukemia is to cure it and achieve remission of leukemia cells. Traditionally, the standardized treatment was chemotherapy which can be divided into intensive chemotherapy and non-intensive. The intensive chemotherapies are two phases of remission induction followed by post-remission consolidation-based therapy. The induction therapy includes drugs such as Cytarabine, Daunorubicin, Idarubicin, and Fludarabine either alone or in combinatorial doses. Consolidation therapy is presented in such cases where induction therapy failed to work, with drugs such as Etoposide, Amsacrine, and Mitoxantrone.

Acute Myeloid Leukemia Market

FLT3 Inhibitors such as Midostaurin and Gilteritinib; IDH Inhibitors such as Enasidenib and Ivosidenib; and Hedgehog pathway inhibitor, such as Glasdegib; BCL-2 inhibitor such as Venetoclax have recently entered the Acute Myeloid Leukemia market as promising targeted therapies with specific genetic mutations. As the first directed agent that works very well in the elderly population with Acute Myeloid Leukemia, Venetoclax and Glasdegib has opened possibilities in the world of targeted therapy. Gilteritinib, Enasidenib, and Ivosidenib were approved explicitly for relapsed and refractory Acute Myeloid Leukemia, with specific genetic mutations. This spell of new drug approvals has altered the Acute Myeloid Leukemia Market and provided new opportunities.

Various companies such as Actinium Pharmaceuticals, AVEO Oncology, Biodesix, Daiichi Sankyo, BioSight, Helsinn Healthcare, Rafael Pharmaceuticals, Otsuka Pharmaceutical, Cyclacel Pharmaceuticals, and others are developing effective therapies, which contribute to the market size of Acute Myeloid Leukemia.

There are many competitors in the development phase for the treatment of AML such as Iomab-B CD45 and Actimab-A CD33 (Actinium Pharmaceuticals), Ficlatuzumab (AVEO Oncology and Biodesix), Devimistat (Rafael Pharmaceuticals), BST236 (BioSight), Bemcentinib (BerGenBio), Pracinostat (Helsinn Healthcare) and others.

#Acute Myeloid Leukemia market #Acute Myeloid Leukemia market share #Acute Myeloid Leukemia market size #Acute Myeloid Leukemia market trends #Acute Myeloid Leukemia market research reports #Acute Myeloid Leukemia epidemiology #Acute Myeloid Leukemia pipeline therapies #Acute Myeloid Leukemia pipeline #Acute Myeloid Leukemia key companies

0 notes

market-analysis · 3 years ago

Text

BCL-2 (B-cell lymphoma 2) Inhibitors Market is estimated to value over USD xx billion by 2027 end and register a CAGR of xx% from the forecast period 2020-2027.

The report initiates from the outline of business surroundings and explains the commercial summary of chain structure. Moreover, it analyses By Indication Type, By Product, By End-User, By Region and BCL-2 (B-cell lymphoma 2) Inhibitors Market.

#BCL-2 (B-cell lymphoma 2) Inhibitors Market #BCL-2 (B-cell lymphoma 2) Inhibitors Market Scope #BCL-2 (B-cell lymphoma 2) Inhibitors Market Analysis #BCL-2 (B-cell lymphoma 2) Inhibitors Market Overview #BCL-2 (B-cell lymphoma 2) Inhibitors Market Trends

0 notes

adityarana1687-blog · 4 years ago

Text

Apoptosis Assay Market Anticipated To Achieve Lucrative Growth Worth $2.3 Billion By 2027

The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.

The flow cytometry segment dominated the market and accounted for the largest revenue share in 2019. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2019 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

Request a free sample copy or view report summary: Apoptosis Assay Market Report

Apoptosis Assay Market Report Highlights

The kits segment dominated the market and accounted for a revenue share of around 50.0% owing to increasing investment by key market players

Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market

Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth

Owing to the wide adoption and easy availability of products, flow cytometry is estimated to account for a substantial share of approximately 35.0% in 2019

The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth

North America has dominated the market in terms of revenue share in 2019, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region

Key companies are competing in terms of a combination of products and services in order to maintain market share.

Apoptosis Assay Market Segmentation

Grand View Research has segmented the global apoptosis assay market on the basis of product, technique, assay type, end-use, and region:

Apoptosis Assay Product Outlook (Revenue, USD Million, 2016 - 2027)

Kits

Reagents

Instruments

Apoptosis Assay Technique Outlook (Revenue, USD Million, 2016 - 2027)

Flow Cytometry

Fluorescence Microscopy

Spectrophotometry

Other Techniques

Apoptosis Assay Type Outlook (Revenue, USD Million, 2016 - 2027)

Caspase

DNA Fragmentation

Cell Permeability

Mitochondrial

Apoptosis Assay End-use Outlook (Revenue, USD Million, 2016 - 2027)

Pharmaceutical & Biotechnology Companies

Hospital & Diagnostic Laboratories

Academic & Research Institutes

Apoptosis Assay Regional Outlook (Revenue, USD Million, 2016 - 2027)

North America

Europe

Asia Pacific

Latin America

MEA

The U.S.

Canada

Germany

The U.K.

France

Italy

Spain

Japan

China

India

Brazil

Mexico

South Africa

Saudi Arabia

List of Key Players of Apoptosis Assay Market

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories

Bio-Techne

Biotium

GeneCopoeia, Inc.

Becton, Dickinson & Company (BD)

Thermo Fisher Scientific, Inc.

Promega Corporation

Sartorius AG

Merck KGaA

Abcam plc.

Takara Bio Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

#Apoptosis Assay Market

1 note · View note

sallowjac · 4 years ago

Link

0 notes

kisan512posts · 4 years ago

Text

Apoptosis -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2022

Apoptosis Industry

Description

Wiseguyreports.Com Adds “Apoptosis -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database

Apoptosis Market research report gives an insight into Apoptosis Mechanism, by Molecular Pathways, Caspase Activators and Inhibitors, Protease/Proteasome Inhibitors, Bcl-2 Modulators, p53 Modulators and Other. The study also focuses on major diseases for which the treatment is based on apoptosis comprising Cancer, Neurodegenerative Diseases, Cardiovascular Diseases and other apoptosis based diseases including HIV infection, Organ Transplant Rejection and MODS. The study provides apoptosis market size related therapeutic products by the above apoptosis molecular pathways and also by the disease areas. The study includes estimates and projections for the total global apoptosis related therapeutic products market. Projections and estimates are also graphically illustrated by geographic regions encompassing North America, Europe, Asia-Pacific and Rest of World. Business profiles of 58 major companies are discussed in the report. The report serves as a guide to global apoptosis market, covering more than 555 companies that are engaged in apoptosis research, testing and supply of products and services. Major Contract Research Organizations and Universities serving apoptosis market are also covered in the Corporate Directory section of this report. Information related product developments, partnerships, collaborations, and mergers and acquisitions are also covered in the report. Compilation of Worldwide Patents and Research related to Apoptosis is provided.

OUR NEW SAMPLE HAVE BEEN UPDATED NOW WHICH CORRESPOND IN NEW REPORT SHOWING IMPACT OF COVID-19 ON INDUSTRY

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/30787-apoptosis-market-research-report

Over the past few years, availability of apoptosis related products (drugs, kits and reagents) has increased enormously. Global market for apoptosis related products is expected to grow at a high CAGR of 31.2% through 2005-2020, and the high growth is owing to increasing evidence of role of apoptosis in mechanism of action for large number of diseases such as Cancer; Neurodegenerative Diseases including Alzheimer’s, Parkinson’s, Multiple Sclerosis and Rheumatoid Arthritis; Cardiovascular Disease; and other apoptosis based diseases including organ transplant rejection and HIV infection. Cancer research has delivered outstanding progress in understanding the biology and genomics of cancer, in the last decade. Foremost of these progress areas is the recognition of apoptosis and its regulatory genes that have an effect on melanoma. In return, other oncogenical changes stimulate apoptosis and override apoptosis during multistage carcinogenesis by making selective pressures. Apoptosis associates cancer therapeutics with cancer genetics by providing conceptual structure, as well as similar changes that suppress apoptosis during tumor development.

Why Buy This Report?

This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

Identify Market Opportunities

Review and Analyze Global and Regional Markets

Gauge Market Potential for your Products

Identify Competition

Use Market Research for exploring new areas

Acquire Meaningful Guidelines for Strategic Planning

Gear up for Market Entry

Get Actionable Information

Leave a Query @ https://www.wiseguyreports.com/enquiry/30787-apoptosis-market-research-report

Analytics and data presented in each report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends

Product (Global and Regional) Market Sizes, Market Shares, Market Trends

Technology Trends

Corporate Intelligence

Key Companies By Sales, Brands, Products

Other Strategic Business Affecting Data

Companies Discussed

50+ Apoptosis Company Insight Profiles

555+ Company Directory Listing

Company Insight Profiles List

Abbott Laboratories (USA)

AbGenomics International (USA)

Aegera Therapeutics, Inc. (Canada)

Æterna Zentaris, Inc. (Canada)

AG Scientific, Inc. (USA)

Amarantus Therapeutics, Inc. (USA)

Amgen, Inc. (USA)

Anavex Life Sciences Corp. (USA)

Antisoma plc (UK)

Aposense Ltd. (Israel)

ArQule, Inc. (USA)

Ascenta Therapeutics, Inc. (USA)

Bayer Schering Pharma AG (Germany)

BD Biosciences (USA)

BioLineRx Ltd. (Israel)

Bioniche Life Sciences Inc. (Canada)

Chroma Therapeutics Ltd. (UK)

Cleveland BioLabs, Inc. (USA)

Critical Outcome Technologies, Inc. (UK)

Cyclacel Pharmaceuticals, Inc. (USA)

D-Pharm Ltd. (Israel)

EntreMed, Inc. (USA)

EpiCept Corporation (USA)

Exelixis, Inc. (USA)

F.Hoffmann-La Roche Ltd. (Switzerland)

GANYMED Pharmaceuticals AG (Germany)

Genentech, Inc. (USA)

Genmab A/S (Denmark)

Genzyme Corporation (USA)

GlaxoSmithKline plc (UK)

Incyte Corporation (USA)

Infinity Pharmaceuticals, Inc. (USA)

Keryx Biopharmaceuticals Inc (USA)

Life Technologies Corporation (USA)

MEI Pharma, Inc. (USA)

MorphoSys AG (Germany)

multimmune GmbH (Germany)

Neuren Pharmaceuticals Limited (New Zealand)

Novartis AG (Switzerland)

Novogen Limited (Australia)

Peregrine Pharmaceuticals, Inc. (USA)

Pfizer, Inc. (USA)

Pharmacyclics, Inc. (USA)

Sigma-Aldrich Co. LLC (USA)

Sunesis Pharmaceuticals, Inc. (USA)

Takeda Pharmaceutical Co., Ltd. (Japan)

Tamir Biotechnology, Inc. (USA)

TetraLogic Pharmaceuticals (USA)

The Institute of Cancer Research (UK)

ZELTIQ (USA)

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=30787

Continued…

NOTE : Our final report have added the analysis of the impact of COVID-19 on this industry, Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

0 notes

databridgemarketresearchblog · 5 years ago

Text

Global Blood Cancer Drug Market Size, Share and Growth Opportunities by 2026

Market Analysis: Global Blood Cancer Drug Market

Global blood cancer drug market is expected to rise gradually to an estimated to register a healthy CAGR of 10.5 % in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Growing cases of hematology-oncology disorders and progressively focusing on innovation of novel therapies are the key drivers for market growth.

Few of the major competitors currently working in the global blood cancer drug market are Eli Lilly and Company, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc, Johnson & Johnson Services. Inc., AbbVie Inc., Amgen Inc. , Bayer AG, Pfizer Inc., AstraZeneca, CELGNE CORPORATION, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA, Sumitomo Dainippon Pharma Co., Ltd, Otsuka Holdings Co., Ltd, Astellas Pharma Inc. and many others..

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-blood-cancer-drug-market

Market Definition: Global Blood Cancer Drug Market

Blood cancer is life threatening oncology disorder in which cancer start growing in the bone marrow, where blood is produced. These tumors prevent the blood from functioning. The patients with blood cancer experience abdominal pain, bone pain, weight loss, dark spots, excessive or easy bruising and weakness. According to the statistic published in American Cancer Society 2019, it is estimated that over 8,110 cases are diagnosed with Hodgkin lymphoma in the United States in this current year. It is more prevalent in teenagers aged 15 to 19 years. Growing incidence of Hodgkin lymphoma worldwide and accelerating demand of clinical treatment and novel therapies indicates the significant growth of market.

Market Drivers

Rise in the incidence and prevalence rate of the disease will drive the growth of the market

Rise in the government and non-government investment in the research and development

Accelerating the demand of novel therapies and treatment

Increases in effectiveness of drugs for the treatment of hematology-oncology disorders

Market Restraints

Patent expiry of blockbuster drugs will result in generic and biosimilar competition

Effective treatment is either unavailable or costly

Inadequate knowledge of blood cancer in developing countries

Segmentation: Global Blood Cancer Drug Market

By Type

Leukemia

Lymphoma

Hodgkin Lymphoma Myeloma

Leukemia Lymphocytic Leukemias

Myeloid leukemias

Others

Acute Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Myeloprolifeative Neoplasms

Systemic Mastocytosis

Hairy Cell Leukaemia (HCL)

Non-Hodgkin Lymphoma

Typical Myeloma

Bence Jones Myeloma

Non-Secretory Myeloma

Immunoglobulin M–Producing Multiple Myeloma

By Therapy Type

Chemotherapy

Immunotherapy

Radiation therapy

Targeted Therapy

By Treatment

Medication

Blood Transfusion

Surgery

By Mechanism of Action Type Proteasome Inhibitor

B-Cell Lymphoma-2 (BCL-2) Protein Inhibitor

Isocitrate Dehydrogenase-1 (IDH1) Inhibitor

Hedgehog Pathway Inhibitor

Anti-CD20 Antibody

Bone Marrow Transplantation

Hematopoietic Stem Cell Transplantation

Bortezomib

Imatinib mesylate

Midostaurin

Gilteritinib

Rituxima Kinase Inhibitor

Venetoclax

Ivosidenib

Enasidenib

Glasdegib

Rituximab

Ibritumomab

By Route of Administration

Oral

Injectable

Intramuscular

Subcutaneous

Intra-arterial

Intravenous

By End users

Hospitals

Homecare

Specialty Clinics

Others

By Geography

North America

South America

Europe

Asia-Pacific

Middle East & Africa

U.S.

Canada

Mexico

Brazil

Argentina

Rest of South America

Germany

France

United Kingdom

Italy

Spain

Russia,

Turkey

Belgium

Netherlands

Switzerland

Rest of Europe

Japan

China

South Korea

India

Australia

Singapore

Thailand

Malaysia

Indonesia

Philippines

Rest of Asia Pacific

South Africa

Egypt

Saudi Arabia

United Arab Emirates

Israel

Rest of Middle East & Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-blood-cancer-drug-market

Key Developments in the Market:

In May 2019, AbbVie Inc. announced that they have received approval from FDA for Venclexta (venetoclax) which is an oral selective B-cell lymphoma-2 (BCL-2) protein inhibitor in combination with obinutuzumab for the treatment of chronic lymphocytic leukemia. With the approval of Venclexta expanded the company’s portfolio in therapeutic area of oncology

In March 2018, Novartis AG received the FDA expanded label approval of Tasigna (nilotinib), a kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) in pediatric patients of age one year or older. This approval broaden the clinical indication of Tasigna

Competitive Analysis: Global Blood Cancer Drug Market

Global blood cancer drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of blood cancer market for global Europe, North America, Asia-Pacific, South America and Middle East & Africa.

#Global Blood Cancer Drug Market

0 notes

thumbkenya76-blog · 6 years ago

Text

AbbVie, Inc. (ABBV) Management Presents at Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)

AbbVie, Inc. (NYSE:ABBV) Morgan Stanley 16th Annual Global Healthcare Conference September 12, 2018 11:40 AM ET

Executives

Bill Chase - Chief Financial Officer

Scott Brun - Head of AbbVie Ventures and VP of Scientific Affairs

Analysts

David Risinger - Morgan Stanley

David Risinger

Okay. So thanks everybody for joining us for the session with AbbVie. I just need to refer you to disclaimers at www.morganstanley.com/researchdisclosures. It’s very much my pleasure to welcome Bill Chase and Scott Brun. So Bill is the Company’s CFO. I’m sure many of you are familiar with him and he’s been in the position for several years and has overseen the Company’s execution of delivering results above expectations for the last several years. Scott is currently Head of AbbVie Ventures and Vice President of Scientific Affairs. He was previously the Head of Pharmaceutical Development and has been instrumental in advancing the Company’s pipeline. So it’s my pleasure to welcome them today. I guess I wanted to start off with a question regarding the execution against your plan.

So, clearly the Company has delivered better than expected performance over a number of years. Investors are skeptical about the longer term given the fear of the biosimilar threats to HUMIRA. So maybe you could sort of tackle it two ways. Talk about the financial targets for 2020 and your confidence in achieving those? And then maybe Scott, you could talk in a bit more detail about the pipeline and its ability to ultimately offset HUMIRA longer term?

Scott Brun

Sure. Well, so David thanks for having us. We always appreciate the opportunity to come out to the Morgan Stanley conference. I think as we start with the big picture and how we’re tracking relative to the long range guidance and particularly in light of that concern around what happens post 2022 when you have an LoE for HUMIRA in the U.S. Like the reality is, since even prior to the spin, this company has been preparing itself for what was going to be in an eventual LoE event around HUMIRA and that was known on day one and our strategy that we said internally and with the board was always trying to build the capabilities and the assets within the Company to be able to negotiate that events and remain a growth vehicle. And at that point in time, we said look our aspirations is to be top tier growth.

Now obviously there's two parts of that equation, one is, what is the HUMIRA curve look like and when, and you've seen us execute very nicely with our legal strategy and the settlements around the U.S. events to delay the onset of LoE in 2022, 2023 time period. The second piece though is what are you going to grow with? And that becomes essentially a pipeline question. And we always knew that we needed to have very, very good differentiated assets. We wanted to be a focus company. We wanted to focus primarily in the areas that we knew that play to our strengths.

So we focus primarily on immunology and oncology. And we set about building what we think is one of the most attractive late stage pipelines in the industry. And we can go through obviously in some detail and Scott's got a lot to say on that thing as well. But at the end of the day, what we called out last time, we updated the strategic plan, isn't if you take HUMIRA out of the mix and you benchmark us back to 2017, which is one of the plan was last updated. We had a business when we looked at our pipeline that we felt was -- we felt comfortable saying was going to grow from about $10 billion in sales size up to $35 billion in 2025.

And the way we're going to do that was through some best in category assets and then which Scott will share with you. Our strong franchise we built in HemOnc with IMBRUVICA and VENCLEXTA products like or at least that we are just underway launching and more recently launched like MAVYRET. And when we look at those assets and we look at the de-risk nature as well as the efficacy and safety that they've shown in a very broad clinical trial, we feel very comfortable that they can get into the market in their respective places and deliver upon those gross projections.

And so we remain very, very confident, pipeline is a huge part of the story. And if you look at our pipeline, not only do we have attractive assets, but this is a very diversified pipeline. We're not delivering all that grows just with one or two assets. There is 5, 6, 7 different aspects at play which we also think is fairly unique when we look at our peers.

David Risinger

Excellent. And maybe Scott, you could add a little bit on and since speak to investors pretty frequently which of the pipeline assets are potentially most underappreciated by investors as you discuss these biggest of pipeline contributors, longer term?

Scott Brun

No, absolutely, I didn't focus on that. Again, David thanks for having us. Bill hit on the number of important themes. When we launched AbbVie, now almost six years ago, focus was incredibly important to make sure that we had the right capabilities from discovery through commercialization market access in a few set areas where we really thought that we could differentiate ourselves with both internally discovered and developed assets as well as externally sourced opportunities. I think that’s been playing out extremely well. I mean I could take the rest of the time going through the qualities of the late-stage pipeline, but maybe I can hit on a few high points.

Certainly, in hematologic malignancies, when you look at it IMBRUVICA and VENCLEXTA, these are two first-in-class agents that are transforming hematologic malignancies of several types. I mean we look at IMBRUVICA the fact is in chronic lymphocytic leukemia, first and second line. It’s really becoming a mainstay of therapy. We've also seen significant results in Waldenstrom's macroglobulinemia. Most recently, we actually had a label update with a study looking in IMBRUVICA combination with Rituxan that again provides us a chemotherapy free option for this particular disease, opportunities in other malignancies like mantle cell lymphoma also tend to build the overall opportunity for IMBRUVICA.

We’re going to continue to progress IMBRUVICA particularly in first line CLL where we think there’s a lot of opportunities in particular in combination with VENCLEXTA first-in-class Bcl-2 inhibitor which have a Phase 2 study captivate to demonstrate the combination of IMBRUVICA and VENCLEXTA can drive to minimal residual disease, essentially no detectable disease by advanced diagnostic methods in 70% to 80% of patients. And so this could really transform the care of CLL away from toxic chemotherapies to a drug combination that could put patients into long-term remission with much less tolerability baggage.

Now talking a little bit more about VENCLEXTA beyond these opportunities in CLL, we’re currently under regulatory review in acute myelogenous leukemia. This is a very devastating rapidly progressive disease that we’ve demonstrated that VENCLEXTA added on to standard-of-care in first line patients who can’t tolerate the harshest chemotherapy can double or triple complete response rates, which led to a breakthrough therapy designation from FDA.

And as I said, current regulatory review that could lead to an approval next year, VENCLEXTA a lot of opportunity in multiple myeloma where we are currently in Phase 3 looking at in combination with Velcade and dexamethasone in second line plus multiple myeloma. We also think there are opportunities in first line myeloma and certain genetically defined population, so a tremendous opportunity is there.

Moving on to our immunology franchise, risankizumab, the partnered assay with BI and anti-IL-23 that has demonstrated some of the highest responses that we’ve seen in patients with psoriasis PASI 100 scores, complete skin clearance on the order of 50% to 60% Superiority versus STELARA, HUMIRA the ability to treat patients who have failed prior TNF inhibitors in a quarterly dosing pattern. And so, risa is currently under regulatory review as well.

Our selective JAK1 inhibitor, upadacitinib, for which we disclosed 5 trials in rheumatoid arthritis. We studied this drug in first line therapy patients who are naive to any treatment, all the way through patients who have failed prior TNF inhibitors. We've lifted Upa with and without methotrexate. We've demonstrated Superiority to HUMIRA. We have over 4,000 patients worth of data. And then every one of these contexts, Upa is performing at the top of the class, certainly directionally, although we have no head-to-head studies directionally better than what we see with baricitinib vs tofacitinib.

I think we've shown from the safety perspective that our rates for venous thromboembolism which has become a point of discussion with this class, really do not differ from placebo and our randomized controlled trials, nor do they worsen overtime, nor do they demonstrate any type of dose response. Certainly, if we want to get into a little bit more of the recent competitive context with recent risa and upa, David during the question we can do that.

ORILISSA, otherwise known as elagolix, the first new therapy for endometriosis related pain in a long time. This disease affects millions of women. They are unsuccessfully treated with combination of oral contraceptives or opioid pain management. We've demonstrated that with this oral therapy that affects the GnRH axis. We can lead to high levels of pain control and do it with a much improved side effect profile relative to show within the nuclear option Lupron.

So, we're in the launch phase of this drug right now. We're in Phase 3 in analysis of bleeding related to uterine fibroid. Another very common gynecological condition where again our two Phase 3 studies that have read out have demonstrated very high levels of efficacy, 75% or so significance of patients had significant reduction in their bleeding.

Again, I could keep going on and on. But I think the point here is as Bill said, diversified assets across a variety of different therapeutic areas that actually have potential beyond these initial indications that I've laid out. And I think as you seen with HUMIRA one of our themes is, to really understand biology and take it to places that it may not have been studied before.

David Risinger

Great. We could just follow up on the competitive landscape…

Scott Brun

We do a couple of announcements over the past year, so…

David Risinger

Yes, could you touch on those?

Scott Brun

Certainly, why don't we go ahead and start with the theme to data and what, I've always got to be careful about talking about someone else who is single study. To sum up what I'll say is based on what we saw from the Phase 2 data in the public domain, I took a Phase 3 data from this first trial or are consistent with that data set?

On the efficacy side both filgotinib and upadacitinib, as I said before directionally appear to provide the potential for improved efficacy relative to baricitinib or tofacitinib. We got to be a careful about our cross-study comparisons here of course especially since we don't know the baseline characteristics of the filgotinib population in total. I would say if you look at the ACR scores, there is puts and takes looking between upa and filgotinib. If you look at some of the DAS scores, which are a high stringent measure of disease control, low disease activity and clinical remission, I can certainly say that, again, all the caveats across study comparisons taking into account that for low dose of upadacitinib is performing every bit as well, if not maybe directionally better than what we see with filgotinib.

So, not seeing clear points of differentiation on the efficacy side, safety is harder to compare because we've got different bits and pieces of what's been shared. I'm glad no patients have venous thromboembolism on the filgotinib trial. But as we know, even patients on background therapy can see VTE. So I think before we can say exactly what that means, we need to see their whole program it's in context. And certainly, we've shared some information on infections, last year so on. I think at this point, it's too early to say that there is any kind of clear signal what differentiation on these low incidence events.

The one thing I do want to point out is that we will be filing an RA with upadacitinib before the end of this year, actually one of the things I must point out, before the end of this year, again, I don't know if Gilead had spoken to their timing when they were just in here. As I understand, the critical path for them is to complete the man-to-male reproductive study to de-risk the 200 milligram dose to see exactly what the benefit risk on that dose is. As I understand that that may put them more than a year behind our current filing timeline.

David Risinger

Got it. That's very helpful. Maybe we could pivot and Bill, you could talk about potential changes in U.S. drug pricing. Obviously, we have to wait and see. And if you could also touch on the notion of rebates going away, it sounds like a pretty big statement. And we'll still need to learn more on what the next steps are from HSS. But it'd be helpful for you to just frame it as you see it currently. And then touch on the rebate issue. Rick had spent a fair amount of time on the 2Q call. So one can refer to that transcript for lots of detail, but still be helpful because it's topic on investors' mind?

Bill Chase

Sure. So look, pricing has been a focus for the industry for the last several years. And it's clear that the administration has made it a focus in these years as well. So we historically whatever we do on our long range plan in the U.S. while we continue to believe the U.S. will remain a price positive environment. We always prudently scale back the rates of increases. So from a long range plan perspective, we've always kind of forecasted because it’s wise to forecast that way that the pricing environment will be getting a little tougher. But beyond the forecast, you've seen actions throughout the industry that have shown the dialogue around price is beginning to have an effect.

So for example, most companies now have moved to one price increase per year. We made a statement couple of years ago that we were doing that. And likewise, price increase is tend to be single digit. We have a statement similar to that as well. And so I think that you are beginning to see an impact through the industry a change in pricing behaviors. And of course, the fall through of those price increases are never in line with list. So I think if you really look at the data right now, you could say on a net-net basis while pricing is still positive in the U.S., it’s probably single-digit fall through, low-single-digit fall through maybe close to medium. But I would say try more like low-single-digits. So it’s clearly having an impact on the industry.

Now, we’re fortunate, we -- our growth is being driven by volume, not by price. If you look at our growth rates this year, they’ve been quite stunning on the top line. Probably last quarter, we had 17% operational growth, I think price overall was about 1% of that. So, when you have new products that are differentiated and you’ve got areas of high unmet need, you can drive impressive top and bottom line performance via volume and that’s what we’ve been doing.

Now, where pricing is going to go from here, little tough to call and obviously we got an initial look at the ideas in the blueprint. But while it was very comprehensive and had some truly creative ideas and we still need to see the details. And so we’re waiting along with the rest of the industry. We haven’t seen major changes to the contracting process to date, because of that. I think it’s kind of, we’re waiting and seeing. Although my guess is, our basic assumption and our long range plan is accurate and pricing will continue to moderate in this market.

In terms of the structural discussion around rebates and the questions that we would need to sort out, I think there’s two really that come to mind. First and foremost is how big, if we move into a paradigm where rebate contracting moves away, right. We move to some other type of contracting. The question is how big of a population of contracts are impacted. The Safe Harbor Provisions directly refers to government business, and the type of contract and that relies on PBM with the government is Medicare. If you look at AbbVie’s U.S. mix about 15% of our business was Medicare.

So, if it just stays within that area, you got 85% of the business in the U.S., which is not impacted. So we need to sort that out and I know some people feel that, it will rapidly move to commercial. We’re not sure, we have to see, how that plays out. That’s an important assumption. But maybe even more important is what rebate contracts are replaced with. We absolutely believe that the government and the market as not going to move away from a scenario, where you can give volume based contracts. It’s kind of a cornerstone of this industry, right. You give contracts based on based on patients under plan, the patient lives under plan and also the ability of that plan to drive compliance via formulary.

And those two things basically add up to a volume based contract. As long as volume based contracting is permitted, we don’t see any reason to believe that it wouldn’t be. It doesn’t really impact our business model. Now, we may need to figure out how you move from a rebate contract to a discount contract. But that’s just, that’s a contract form, it wouldn’t change the overall strategy. So yes, I understand why there’s a lot of concern around this change. But at the end of the day, I think it has less impact on manufacturers then perhaps the PBMs.

David Risinger

That’s extremely helpful. Let me pause there and see if there are any questions before I continue.

Question-and-Answer Session

Q - David Risinger

Okay. So one of the other topics that came up earlier in the year was the co-pay accumulator programs on the part of payers, and obviously, that has some marginal negative impact on reported sales. But could you just recap that and talk about how much of an inflection might be if more payers adopt such accumulators in 2019?

Bill Chase

Yes, sure. So, what we saw play out in the first quarter of 2018 was that there was a significant portion of patients that found themselves on high deductible plans with a co-pay accumulator. That number was roughly 4% to 5% of our commercial business which is about 80%. I'm talking to HUMIRA for example, okay. So if not necessarily not the lion's share, but it's a meaningful portion of patients.

And with this co-pay accumulator, especially did this concept was it ultimately ensured that the patient was on the hook for the full deductible even in the event that the manufacturer was willing to extend a co-pay card. Now, we fundamentally believe one of the issues in healthcare industry is co-pays that patients are burdened with. And so in most cases where we're able to, we offer co-pay assistance in order to alleviate that burden and that out of pocket burden on the consumer, the patient. We think that's absolutely the right thing to do.

What was somewhat perverse about the co-pay accumulators is it essentially could block our ability to do that. And so our view is, it is absolutely a poor contract form. And furthermore, we believe that a lot of people that were in co-pay accumulators may not clearly in plans that had co-pay accumulator, may not clearly understand what the ramifications for those plans were. And we're going to get surprise in the second quarter when they found out that their co-pay assistance have the limited a fixed amount and they now had to pay the deductible. And these deductible could be anywhere at $3,000 or $4,000. So a meaningful hit to your average patient, which in normal course would be covered by co-pay assistance and would not be taxing the patient out of pocket.

So, they get absolutely a horrific insurance form for the patient, it's actually rations their ability to get medications they need. And frankly the medications that we're selling, whether it be HUMIRA or anything else that we've got in our portfolio, these are for life threatening illnesses. And so to basically to private patients of access to that, that therapeutic, based on their ability to pay out of pocket, that was just absolutely the wrong thing to do.

So we recognize that this issue existed, we recognize that a lot of patients might be surprised. It was going to play out in Q2 and Q3 because really frankly, they had to burn through their co-pay cards before they discovered that they're still on the hook for the deductible. And in our Q1 call, we did adjust our HUMIRA guidance number down slightly to account for additional co-pay assistance that we would be able to provide these patients until we were able to sort themselves through this situation.

So, it came up as an issue on our first quarter comp. What I can tell you is it's largely tracking in line with what our expectations were. I think that the measures we've taken have largely been effective. There's been a lot of patient education by patient groups over the nature of these programs. So I like to think that we have wiser patients that will, if to the extent that they can avoid these sorts of insurance constructs in 2019, we certainly think there'll be inclined to do so.

And right now as we forecast '19, we don't see this patient population or the patient population that subject to this form of insurance coverage as expanding dramatically. We think it will largely be contained in a number roughly the size that we're seeing in '18.

David Risinger

Okay that's very helpful. And Scott, maybe we could pivot to IMBRUVICA. So there is an interesting Phase 3 trial in pancreatic cancer that's supporting out soon. Could you just frame that for us?

Scott Brun

Yes, absolutely. David, I mean, again it's better to go back and remind you all the overall strategy when we proceeded with the Pharmacyclics deal. So we felt that, look the foundation of this asset was going to be in the type of hematologic malignancies that I have spoken to particularly CLL. As you progress beyond there, we have increasing levels of risk adjustment that's spoken about some of the other malignancies where we seen great promise. PHOENIX in first line diffuse large B-cell lymphoma didn't measure up the expectations. That's a discrete duration of therapy against difficult effective standard of care, R-CHOP.

But again because of those considerations even the fact that we don't successful there, didn't mitigate our overall expectations for the assay. I would put pancreatic cancer in even another lower bucket with regard to the probability of success that we would apply to that. Obviously, this is a devastating condition for which there exist few good options. And so, we have a Phase 3 trial that is looking at IMBRUVICA added on to paclitaxel gemcitabine. That should be reading out before the end of the year, but again, this is high hurdle, haven't seen the data yet. But certainly, we don't have appropriate expectations for that.

Some of the other trials on IMBRUVICA that will be reading out, well certainly, we talked about CLL and again the iLLUMINATE trial which what's at IMBRUVICA plus GAZYVA versus chlorambucil GAZYVA to continue to enhance our body of data in first line CLL. We top line that and I think maybe able to say more on that at ASH. And then we've got ongoing study that we'll be reading out more in the 2019-2020 timeframe and things like follicular lymphoma first line mantle cell in particular.

David Risinger

Excellent. Well, I think we are out of time. I think we can go on the lot longer, but unfortunately we're out of time. So thank you so much for joining us. Appreciate that.

Source: https://seekingalpha.com/article/4205875-abbvie-inc-abbv-management-presents-morgan-stanley-16th-annual-global-healthcare-conference?source=feed_all_articles

0 notes